title: [Rapidly progressive glomerulonephritis in ANCA-associated vasculitis: a course, treatment efficacy, prognosis].
abstract: OBJECTIVE
  To study efficacy of ANCA-RPGN treatment with corticosteroids and cyclophosphamide or mycophenolic acid drugs.
  
  
  METHODS
  We treated 28 patients (17 males and 11 females aged 19-71 years) with morphologically verified ANCA-associated crescentic RPGN (crescentic median 79 (63:88)%. The patients received corticosteroids and cytostatics.
  
  
  RESULTS
  The response to the treatment was registered in 22 (78%) patients in 8-16 weeks: a complete remission was achieved in 8 patients, a partial one--in 14 patients. In partial remission renal functions recovered incompletely (median Pcr 200 (180;255) mcmol/l) in persistence of moderate proteinuria (median 0.7 (0.6;1.3)g/day) and absence of microhematuria. Probability of the treatment success depended on severity of glomerulosclerosis and weakly depended on activity of extracapillary reaction. Severe renal failure was not an absolute predictor of treatment failure.
  
  
  CONCLUSIONS
  In the absence of advanced nephrosclerosis early treatment with corticosteroid in combination with cytostatics can produce a positive effect in 70-80% patients with ANCA associated RPGN.
authors.forename: N A
authors.initials: NA
authors.lastname: Tomilina
authors.forename: L S
authors.initials: LS
authors.lastname: Biriukova
authors.forename: E T
authors.initials: ET
authors.lastname: Egorova
authors.forename: A V
authors.initials: AV
authors.lastname: Sukhanov
authors.forename: E S
authors.initials: ES
authors.lastname: Stoliarevich
authors.forename: O A
authors.initials: OA
authors.lastname: Kupavtseva
authors.forename: N D
authors.initials: ND
authors.lastname: Fedorova
authors.forename: A V
authors.initials: AV
authors.lastname: Frolov
authors.forename: R N
authors.initials: RN
authors.lastname: Trushkin
authors.forename: L G
authors.initials: LG
authors.lastname: Kurenkova
mesh_terms: D000328:Adult; D000368:Aged; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D014657:Vasculitis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide